Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Eurofins Scientific SE    ERF   FR0014000MR3

EUROFINS SCIENTIFIC SE

(ERF)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eurofins Scientific : Ten-For-One Stock Split Now Approved by Extraordinary General Meeting

11/16/2020 | 11:41am EST

Regulatory News:

Following the announcement published on 16 October 2020 and the Extraordinary General Meeting held today, 16 November, Eurofins (Paris:ERF) announces that the resolution proposing a ten-for-one stock split has been passed by the requisite majority.

The existing shares with a nominal value of ten eurocent (EUR 0.10) will be cancelled and each replaced by ten new shares with a nominal value of one eurocent (EUR 0.01). The stock split will become effective upon the listing on Euronext Paris of the new shares on 19 November 2020 (new ISIN: FR0014000MR3).

About Eurofins – the global leader in bio-analysis

Eurofins Scientific, through its subsidiaries (hereinafter “Eurofins” or “the Group”), believes it is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric and molecular clinical diagnostic testing. With over 50,000 staff across a network of more than 900 independent companies in over 50 countries generally specialised by end client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services. The Group’s objective is to provide its customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly-qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.

As one of the most innovative and quality-oriented international groups in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.


© Business Wire 2020
All news about EUROFINS SCIENTIFIC SE
01/18EUROFINS SCIENTIFIC : Bioanalytical Services launches Surrogate Virus Neutralizi..
PU
01/15Eurofins Launches New Test, Increased Capacity to Detect SARS-CoV-2 Variants
MT
01/15EUROFINS : the global leader in analytical testing, expands worldwide face mask ..
BU
01/15EUROFINS SCIENTIFIC : Launches New Tests and Massive Capacity for Detecting and ..
BU
01/11EUROFINS SCIENTIFIC : Anti-COVID-19 System Gets Emergency Response Validation PT..
MT
01/11EUROFINS SCIENTIFIC : GeneScan Technologies Announces AOAC PTM Accreditation for..
BU
2020EUROFINS SCIENTIFIC : Launches Full-Length COVID-19Viral Genome Sequencing Servi..
MT
2020EUROFINS SCIENTIFIC : Genomics Launches Cost-Effective SARS-CoV-2 full-length Vi..
BU
2020EUROFINS CEREP : Launches PCR COVID-19 Self-Test In Germany, Spain
MT
2020EUROFINS SCIENTIFIC : launches COVID-19 PCR tests with at-home self-sampling opt..
PU
More news
Financials
Sales 2020 5 270 M 6 413 M 6 413 M
Net income 2020 405 M 493 M 493 M
Net Debt 2020 2 816 M 3 426 M 3 426 M
P/E ratio 2020 37,6x
Yield 2020 0,65%
Capitalization 14 882 M 18 116 M 18 110 M
EV / Sales 2020 3,36x
EV / Sales 2021 3,10x
Nbr of Employees 48 000
Free-Float 66,7%
Chart EUROFINS SCIENTIFIC SE
Duration : Period :
Eurofins Scientific SE Technical Analysis Chart | ERF | FR0014000MR3 | MarketScreener
Technical analysis trends EUROFINS SCIENTIFIC SE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 73,97 €
Last Close Price 78,00 €
Spread / Highest target 9,10%
Spread / Average Target -5,16%
Spread / Lowest Target -51,0%
EPS Revisions
Managers and Directors
NameTitle
Gilles J. Martin Chairman & Chief Executive Officer
Laurent Lebras Director-Group Finance & Administration
Andreas König Chief Information Officer
Yves-Loïc Martin Non-Executive Director
Valérie Hanote Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
EUROFINS SCIENTIFIC SE13.65%18 116
SQUARE, INC.2.41%100 505
FISERV, INC.-5.78%71 925
GLOBAL PAYMENTS INC.-12.95%56 132
OFFCN EDUCATION TECHNOLOGY CO., LTD.6.49%35 597
CINTAS CORPORATION-8.20%34 080